[Impact of GP IIb/IIIa antagonists in interventional cardiology]

Dtsch Med Wochenschr. 2003 Feb 7;128(6):281-7. doi: 10.1055/s-2003-37078.
[Article in German]
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Abciximab
  • Acute Disease
  • Angina Pectoris / drug therapy*
  • Angina Pectoris / therapy*
  • Angioplasty, Balloon, Coronary*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Clinical Trials as Topic
  • Drug Therapy, Combination
  • Eptifibatide
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage
  • Immunoglobulin Fab Fragments / therapeutic use*
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / therapy*
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Risk Factors
  • Stents*
  • Syndrome
  • Thrombolytic Therapy
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Eptifibatide
  • Abciximab